AstraZeneca Pharmaceuticals Inc., has launched its second patent infringement suit against Mylan Pharmaceuticals Inc., in response to the generic-drug maker's most recent bid for regulatory approval to manufacture a copycat version of schizophrenia treatment Seroquel XR®. The drugmaker claims in the suit lodged Monday in the U.S. District Court for the Northern District of West Virginia that Mylan infringed U.S. Patent Numbers 4,879,288 and 5,948,437 through its submission of an abbreviated new drug application for permission to manufacture a 200 mg strength version of generic Seroquel XR®. AstraZeneca seeks a declaration that both patents remain valid and enforceable and are directly and willfully infringed by the generics maker's second ANDA filing. The complaint also asks the court to consolidate the instant suit with the earlier action against Mylan, as well as with nine additional suits currently pending in the District of New Jersey. AstraZeneca is represented by Finnegan.
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.